Additional file 1: of NmeCas9 is an intrinsically high-fidelity genome-editing platform

Figure S1. (A) Sequences of sgRNAs associated with their respective DNA targets used in Fig. 1b. (B) Schematic representation of the split-GFP reporter system used in Figs. 1b, 2a, and 6a. Figure S2. NmeCas9 does not lead to an increase in γH2AX levels in mouse ESC or human HEK293T cells. Figure S3. SpyCas9 and NmeCas9 exhibit similar editing activity when targeting the AAVS1 locus. Figure S4. NmeCas9 and SpyCas9 editing efficiencies at dual target sites (DTSs) that can be cleaved by both enzymes. Figure S5. SITE-Seq read counts and heat map of the frequencies of indels by length at DTS3, DTS7, and DTS8 for SpyCas9 and NmeCas9. Figure S6. Positions of insertions and deletions at the DTS3, DTS7, and DTS8 sites. Figure S7. Sizes of insertions and deletions at the DTS3, DTS7, and DTS8 sites. Figure S8. Fractions of all mutations that are insertions or deletions at the DTS3, DTS7, and DTS8 sites for SpyCas9 and NmeCas9. Figure S9. As in Figure S6. Figure S10. As in Figure S7. Figure S11. GUIDE-seq read counts at NmeCas9 on- and off-target sites. Figure S12. Guide truncation series for Protospacer 9, NTS33 and NTS32. Figure S13. GUIDE-seq analysis to determine whether NmeCas9 sgRNA truncation leads to de novo off-target events. Figure S14. NmeCas9 guide length requirements at the NTS1C and NTS1C-OT1 editing sites. (PDF 5232 kb